X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-11-19 | IMTX | Immatics N.V. | Kramer Rainer | Chief Business Officer | S - Sale+OE | $6.06 | -22,868 | 0 | -100% | -$138,580 | |||||
2026-11-19 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $16.13 | -48,202 | 1,310,002 | -4% | -$777,498 | ||||||
2026-11-18 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $16.51 | -10,269 | 386,609 | -3% | -$169,541 | ||||||
2026-11-18 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $16.51 | -32,717 | 70,948 | -32% | -$540,158 | ||||||
2026-11-19 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.13 | +50,000 | 436,095 | +13% | +$6,550 | ||||||
| D | 2026-11-17 | LCTX | Lineage Cell Therapeutics, Inc. | Broadwood Partners, L.P. | Dir, 10% | P - Purchase | $0.77 | +1,000,000 | 101,209,612 | +1% | +$770,700 | |||||
| D | 2026-11-17 | BSEM | Biostem Technologies, Inc. | Matuszewski Jason | CEO, 10% | S - Sale+OE | $1.00 | -14,300 | 1,539,251 | -1% | -$14,300 | |||||
2026-11-17 | PALI | Palisade Bio, Inc. | Baltera Robert Jr. | Dir | P - Purchase | $1.01 | +50,000 | 511,904 | +11% | +$50,285 | ||||||
2026-11-17 | LCTX | Lineage Cell Therapeutics, Inc. | Mulroy Michael H. | Dir | P - Purchase | $0.87 | +30,000 | 328,555 | +10% | +$26,100 | ||||||
| D | 2026-11-17 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale+OE | $164.87 | -15,000 | 122,141 | -11% | -$2,473,030 | |||||
2026-11-17 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $5.57 | +5,000 | 59,980 | +9% | +$27,850 | ||||||
2026-11-18 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.13 | +20,000 | 386,095 | +5% | +$2,680 | ||||||
2026-11-17 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.32 | -3,499 | 536,283 | -1% | -$1,122 | ||||||
2026-11-17 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.32 | -3,223 | 259,850 | -1% | -$1,034 | ||||||
2026-11-16 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $21.60 | -16,198 | 208,017 | -7% | -$349,877 | ||||||
2026-11-16 | REPL | Replimune Group, Inc. | Schwendenman Andrew | Chief Accounting Officer | S - Sale | $21.60 | -2,148 | 97,277 | -2% | -$46,397 | ||||||
2026-11-16 | REPL | Replimune Group, Inc. | Patel Sushil | CEO | S - Sale | $21.60 | -49,026 | 659,125 | -7% | -$1,058,962 | ||||||
2026-11-16 | REPL | Replimune Group, Inc. | Hill Emily Luisa | CFO | S - Sale | $21.60 | -14,709 | 201,143 | -7% | -$317,714 | ||||||
2026-11-18 | HALO | Halozyme Therapeutics, Inc. | Posard Matthew L. | Dir | S - Sale | $96.43 | -5,000 | 48,609 | -9% | -$482,147 | ||||||
| D | 2026-11-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $167.87 | -27,160 | 286,307 | -9% | -$4,559,209 | |||||
2026-11-16 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $6.46 | -6,094 | 126,681 | -5% | -$39,368 | ||||||
| D | 2026-11-16 | WWB | Windward Bio Group AG | Bonita David P | Dir, 10% | P - Purchase | $17.00 | +1,176,471 | 7,097,483 | +20% | +$20,000,007 | |||||
| D | 2026-11-16 | WWB | Windward Bio Group AG | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $17.00 | +1,176,471 | 7,097,483 | +20% | +$20,000,007 | |||||
2026-11-17 | LXEO | Lexeo Therapeutics, Inc. | Tamayo Louis Edward | CFO | S - Sale | $3.26 | -1,007 | 91,900 | -1% | -$3,283 | ||||||
2026-11-17 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | COO | S - Sale | $3.26 | -1,285 | 137,003 | -1% | -$4,189 | ||||||
2026-11-17 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $3.26 | -3,295 | 373,483 | -1% | -$10,742 | ||||||
| DM | 2026-11-16 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $215.63 | -78,375 | 1,467,144 | -5% | -$16,900,019 | |||||
| D | 2026-11-16 | WWB | Windward Bio Group AG | Stampacchia Otello | Dir | P - Purchase | $17.00 | +1,750,000 | 5,338,520 | +49% | +$29,750,000 | |||||
2026-11-18 | CGON | Cg Oncology, Inc. | Kuan Arthur | CEO | P - Purchase | $78.88 | +30,000 | 228,916 | +15% | +$2,366,425 | ||||||
2026-11-18 | CGON | Cg Oncology, Inc. | Kalofonos Isabel | Chief Commercial Officer | P - Purchase | $79.76 | +3,751 | 3,751 | New | +$299,161 | ||||||
2026-11-17 | ARTV | Artiva Biotherapeutics, Inc. | Miralles Gines Diego | Pres, Head of R, D | S - Sale | $3.91 | -1,043 | 121,457 | -1% | -$4,080 | ||||||
2026-11-17 | ARTV | Artiva Biotherapeutics, Inc. | Horan Christopher | Chief Tech Operations Officer | S - Sale | $3.91 | -20,546 | 281,775 | -7% | -$80,374 | ||||||
2026-11-17 | ARTV | Artiva Biotherapeutics, Inc. | Bush Jennifer | COO, CLO, Compliance Officer | S - Sale | $3.91 | -19,217 | 338,503 | -5% | -$75,175 | ||||||
2026-11-16 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $103.69 | -5,427 | 87,283 | -6% | -$562,715 | ||||||
2026-11-16 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $103.69 | -12,752 | 239,367 | -5% | -$1,322,229 | ||||||
2026-11-16 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $103.69 | -4,281 | 128,145 | -3% | -$443,888 | ||||||
| D | 2026-11-16 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $103.69 | -19,045 | 670,906 | -3% | -$1,974,738 | |||||
2026-11-16 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $103.69 | -1,637 | 53,212 | -3% | -$169,737 | ||||||
2026-11-16 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $103.69 | -6,359 | 126,329 | -5% | -$659,352 | ||||||
2026-11-17 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale | $3.91 | -4,037 | 164,701 | -2% | -$15,792 | ||||||
2026-11-17 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $3.91 | -119,771 | 1,337,657 | -8% | -$468,532 | ||||||
2026-11-17 | CMPX | Compass Therapeutics, Inc. | Lerner Neil | CHIEF ACCOUNTING OFFICER | P - Purchase | $0.59 | +10,000 | 430,000 | +2% | +$5,900 | ||||||
2026-11-17 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $8.45 | -62,000 | 1,239,595 | -5% | -$523,900 | ||||||
| D | 2026-11-16 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale+OE | $170.56 | -28,000 | 110,684 | -20% | -$4,775,527 | |||||
2026-11-16 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $171.47 | -3,000 | 158,096 | -2% | -$514,410 | ||||||
2026-11-13 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $80.31 | -10,000 | 851,412 | -1% | -$803,100 | ||||||
2026-11-16 | LCTX | Lineage Cell Therapeutics, Inc. | Andrews Deborah J | Dir | P - Purchase | $0.80 | +25,000 | 40,578 | +160% | +$20,000 | ||||||
| D | 2026-11-16 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $92.00 | -1,000 | 1,000 | -50% | -$92,000 | |||||
| D | 2026-11-13 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale+OE | $57.71 | -1,885 | 1,259 | -60% | -$108,779 | |||||
2026-11-16 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.14 | +38,000 | 366,095 | +12% | +$5,130 | ||||||
2026-11-16 | LCTX | Lineage Cell Therapeutics, Inc. | Culley Brian M | Pres, CEO | P - Purchase | $0.92 | +40,500 | 296,016 | +16% | +$37,098 | ||||||
| D | 2026-11-16 | ADMA | Adma Biologics, Inc. | Guiheen Lawrence P. | Dir | S - Sale+OE | $13.92 | -10,000 | 186,510 | -5% | -$139,200 | |||||
| D | 2026-11-16 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $13.72 | -21,000 | 3,789,160 | -1% | -$288,120 | |||||
| DM | 2026-11-12 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $100.01 | -60,000 | 767,780 | -7% | -$6,000,686 | |||||
| D | 2026-11-13 | FENC | Fennec Pharmaceuticals Inc. | Brughera Marco Maria | Dir | S - Sale+OE | $12.00 | -20,000 | 0 | -100% | -$240,000 | |||||
2026-11-12 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $0.00 | -20,429 | 126,054 | -14% | -$0 | ||||||
| D | 2026-11-12 | GILD | Gilead Sciences, Inc. | Kramer Kelly A. | Dir | S - Sale+OE | $169.76 | -10,376 | 1,339 | -89% | -$1,761,437 | |||||
2026-11-13 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $5.92 | +14,980 | 54,980 | +37% | +$88,679 | ||||||
| DM | 2026-11-11 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $29.73 | -35,228 | 377,802 | -9% | -$1,047,303 | |||||
2026-11-11 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $32.00 | -1,875 | 387,475 | 0% | -$60,000 | ||||||
| D | 2026-11-11 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $188.10 | -35,750 | 119,216 | -23% | -$6,724,688 | |||||
2026-11-11 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $2.42 | -21,164 | 265,592 | -7% | -$51,122 | ||||||
2026-11-11 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $2.42 | -7,814 | 70,379 | -10% | -$18,875 | ||||||
2026-11-11 | ALDX | Aldeyra Therapeutics, Inc. | Douglas Richard | Dir | P - Purchase | $0.64 | +200,000 | 395,000 | +103% | +$128,900 | ||||||
2026-11-12 | CCCC | C4 Therapeutics, Inc. | Adams Kendra | CFO | S - Sale | $2.71 | -45,173 | 337,150 | -12% | -$122,487 | ||||||
| D | 2026-11-11 | PCVX | Vaxcyte, Inc. | Dhaliwal Harpreet S. | Chief Technical Ops Officer | S - Sale+OE | $67.83 | -17,000 | 68,085 | -20% | -$1,153,103 | |||||
2026-11-11 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.15 | +35,000 | 328,095 | +12% | +$5,215 | ||||||
| DM | 2026-11-09 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | CFO | S - Sale+OE | $58.26 | -25,008 | 16,186 | -61% | -$1,456,978 | |||||
| D | 2026-11-10 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $58.96 | -7,000 | 18,300 | -28% | -$412,720 | |||||
| D | 2026-11-09 | VCEL | Vericel Corp | Zerbe Robert L Md | Dir | S - Sale+OE | $57.88 | -2,000 | 32,995 | -6% | -$115,760 | |||||
| D | 2026-11-09 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $200.00 | -811 | 39,765 | -2% | -$162,200 | |||||
| D | 2026-11-11 | IMVT | Immunovant, Inc. | Pande Atul | Dir | S - Sale+OE | $36.00 | -3,000 | 136,731 | -2% | -$108,000 | |||||
2026-11-10 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC | S - Sale | $9.75 | -2,821 | 56,782 | -5% | -$27,505 | ||||||
2026-11-10 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.14 | +39,000 | 293,095 | +15% | +$5,382 | ||||||
| M | 2026-11-06 | ETRA | Electra Therapeutics, Inc. | Gordon Carl L | Dir, 10% | P - Purchase | $8.08 | +92,116 | 2,194,579 | +4% | +$744,531 | |||||
| M | 2026-11-06 | ETRA | Electra Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $8.08 | +92,116 | 2,194,579 | +4% | +$744,531 | |||||
| DM | 2026-11-09 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $29.82 | -23,762 | 377,802 | -6% | -$708,558 | |||||
2026-11-09 | REPL | Replimune Group, Inc. | Slattery Joseph P | Dir | S - Sale | $21.80 | -5,200 | 1,467 | -78% | -$113,360 | ||||||
2026-11-09 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.16 | +31,298 | 254,095 | +14% | +$5,070 | ||||||
2026-11-06 | GILD | Gilead Sciences, Inc. | Cain Wettan Keeley M | EVP GC, Legal, Comp | S - Sale | $164.11 | -3,399 | 5,360 | -39% | -$557,810 | ||||||
| DM | 2026-11-05 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | CFO | S - Sale+OE | $53.48 | -50,000 | 16,186 | -76% | -$2,674,019 | |||||
2026-11-06 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.16 | +12,751 | 222,797 | +6% | +$2,015 | ||||||
| DM | 2026-11-04 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $26.78 | -35,643 | 377,802 | -9% | -$954,442 | |||||
| DM | 2026-11-04 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale+OE | $175.16 | -112,429 | 551,683 | -17% | -$19,693,439 | |||||
| D | 2026-11-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $12.36 | -4,000 | 158,649 | -2% | -$49,440 | |||||
| M | 2026-11-04 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $98.51 | +247,090 | 20,424,859 | +1% | +$24,340,836 | |||||
| D | 2026-11-05 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale+OE | $52.90 | -1,500 | 1,259 | -54% | -$79,350 | |||||
| D | 2026-11-05 | VCEL | Vericel Corp | Flynn Sean C. | GC | S - Sale+OE | $51.92 | -15,000 | 1,990 | -88% | -$778,800 | |||||
| DM | 2026-11-04 | VCEL | Vericel Corp | Zerbe Robert L Md | Dir | S - Sale+OE | $49.12 | -5,500 | 32,995 | -14% | -$270,175 | |||||
2026-11-06 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.16 | +20,299 | 210,046 | +11% | +$3,167 | ||||||
2026-11-05 | AGMB | Agomab Therapeutics Nv | Epstein David R | Dir | P - Purchase | $6.90 | +15,000 | 40,000 | +60% | +$103,500 | ||||||
| D | 2026-11-05 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $12.00 | -147,000 | 3,795,160 | -4% | -$1,764,000 | |||||
| M | 2026-11-03 | ETRA | Electra Therapeutics, Inc. | Gordon Carl L | Dir, 10% | P - Purchase | $7.63 | +472,571 | 2,136,979 | +28% | +$3,605,116 | |||||
| M | 2026-11-03 | ETRA | Electra Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $7.63 | +472,571 | 2,136,979 | +28% | +$3,605,116 | |||||
2026-11-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $1.52 | -266 | 502,641 | 0% | -$404 | ||||||
2026-11-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $135.40 | -949 | 62,840 | -1% | -$128,496 | ||||||
2026-11-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $135.40 | -2,565 | 180,278 | -1% | -$347,306 | ||||||
| D | 2026-11-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $135.40 | -4,573 | 558,187 | -1% | -$619,193 | |||||
2026-11-03 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $135.40 | -148 | 42,769 | 0% | -$20,039 | ||||||
2026-11-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $135.40 | -1,007 | 105,625 | -1% | -$136,350 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |